aripiprazole has been researched along with lassbio-579 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonio, CB; Barreiro, EJ; Fraga, CA; Grazziottin, LR; Menegatti, R; Neves, G; Noël, F; Rates, SM; Vieira, RO | 1 |
| Barreiro, EJ; Bosier, B; Fraga, CA; Hermans, E; Menegatti, R; Monteiro do Monte, F; Noël, F; Pompeu, TE | 1 |
2 other study(ies) available for aripiprazole and lassbio-579
| Article | Year |
|---|---|
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Cell Line; Humans; Ligands; Male; Mice; Piperazines; Pyrazoles; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia | 2010 |
Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor.
Topics: Antipsychotic Agents; Aripiprazole; Cell Membrane; Clozapine; Corpus Striatum; Dopamine Agonists; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; HEK293 Cells; Humans; Kinetics; Piperazines; Radioligand Assay; Receptors, Dopamine D2; Transfection | 2015 |